Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ETLAS-2
NCT05173896Phase 2Active, not recruiting
- Start
- May 2022
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Cerebral Small Vessel Disease (CSVD) comparing Tadalafil with Placebo (2 arms). Primary endpoint: Feasibility of treatment at 3 months. Started May 2022; status: active, not recruiting.
02
Drugs
tadalafil
03
Conditions
Cerebral Small Vessel Disease (CSVD)
Beyond the preview
Go deeper on NCT05173896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05173896.